BioCentury
ARTICLE | Clinical News

Kadcyla trastuzumab emtansine regulatory update

April 28, 2014 7:00 AM UTC

The U.K.'s NICE issued a preliminary appraisal recommending against the use of Kadcyla trastuzumab emtansine from Roche to treat HER2-positive, unresectable, locally advanced or metastatic breast cancer in patients who previously received Herceptin trastuzumab and/or a taxane - Kadcyla's approved indication in the EU. The committee said the most plausible incremental cost-effectiveness ratio (ICER) for Kadcyla compared to Tyverb lapatinib plus Roche's Xeloda capecitabine was £185,000 ($311,022) per quality-adjusted life year (QALY) gained, above the limit normally considered cost-effective. Roche did not submit a patient access scheme. Comments are due May 19, with a second appraisal committee meeting scheduled for May 28. ...